What is the recommended prophylaxis and treatment for tumor lysis syndrome in an adult receiving chemotherapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Tumor Lysis Syndrome: Prophylaxis and Treatment in Adults Receiving Chemotherapy

Risk Stratification is Critical

For adults receiving chemotherapy, high-risk patients should receive rasburicase (0.20 mg/kg/day IV over 30 minutes) plus aggressive hydration in an inpatient setting, while low-risk patients should receive oral allopurinol (100 mg/m² three times daily, maximum 800 mg/day) plus hydration and urine alkalinization 1.

Identifying High-Risk Patients

Before initiating prophylaxis, you must stratify risk based on three categories 1:

Host-related factors:

  • Pre-existing renal impairment
  • Obstructive uropathy
  • Dehydration
  • Hyperuricemia (>10 mg/dL in adults)

Disease-related factors:

  • High-grade lymphomas (particularly Burkitt's lymphoma, T-cell lymphoblastic NHL)
  • Acute lymphoblastic leukemia in adults
  • Bulky disease or massive liver metastases
  • Metastatic germ cell tumors
  • Elevated LDH (>2× upper normal limit)

Therapy-related factors:

  • Intensive polychemotherapy (cisplatin, cytarabine, etoposide, methotrexate)

Pre-Treatment Evaluation

Obtain these baseline studies in all patients 1:

  • Creatinine clearance or estimated GFR
  • Serum LDH levels
  • Renal ultrasound

Prophylaxis Protocols

High-Risk Patients

Rasburicase is the cornerstone of high-risk prophylaxis 1:

  • Dose: 0.20 mg/kg/day IV over 30 minutes
  • Timing: First dose at least 4 hours before chemotherapy
  • Duration: 3-5 days minimum
  • Do NOT give concurrent allopurinol (causes xanthine accumulation and removes substrate for rasburicase)
  • After rasburicase completion, transition to oral allopurinol 1

Critical contraindications to rasburicase 2, 1:

  • G6PD deficiency (screen patients of African American, Mediterranean, or Southeast Asian descent)
  • Pregnancy or lactation
  • Known hypersensitivity to urate oxidase
  • Metahemoglobinemia

For patients with these contraindications, use allopurinol, hydration, and urine alkalinization instead 1.

Low-Risk Patients

  • Allopurinol: 100 mg/m² orally three times daily (maximum 800 mg/day) 1
  • Start: 1-2 days before chemotherapy 2
  • Continue: 3-7 days after chemotherapy based on ongoing risk 2
  • Adjust dose in renal impairment (drug accumulates) 1

Hydration Protocol (All Risk Levels)

Hydration is fundamental to both prophylaxis and treatment 1:

  • Start: At least 48 hours before chemotherapy when possible
  • Target urine output: ≥100 mL/hour in adults
  • Monitor: Urine osmolality and fractional excretion of sodium to assess hydration status
  • Loop diuretics: May be needed to maintain urine output, but check hemodynamic status first and avoid in obstructive uropathy or hypovolemia

Important caveat: Do NOT alkalinize urine in patients receiving rasburicase (increases calcium phosphate precipitation and reduces xanthine solubility) 1. Urine alkalinization is only for low-risk patients on allopurinol.

Treatment of Established TLS

Once TLS develops, this is an oncologic emergency requiring ICU-level care 1, 3:

Immediate Interventions

For hyperuricemia:

  • Rasburicase: 0.10-0.2 mg/kg daily (treatment dose may be higher than prophylaxis) 2
  • Duration: 1-7 days (average 3 days), guided by uric acid levels
  • In massive tumor lysis, may need twice-daily dosing 2
  • Stop when uric acid is extremely low or undetectable 2

For hyperphosphatemia:

  • Phosphate binders
  • Avoid calcium-containing products (risk of calcium phosphate precipitation)

For hyperkalemia:

  • Standard hyperkalemia management protocols
  • May require urgent dialysis

For hypocalcemia:

  • Only treat if symptomatic (to avoid calcium phosphate precipitation)

Monitoring in Established TLS

First 24 hours - every 6 hours 1:

  • Vital signs (heart rate, blood pressure, urine output, respiratory rate)
  • Serum uric acid
  • Electrolytes (potassium, phosphate, calcium)
  • Renal function (creatinine, BUN)
  • Urine pH, osmolality, specific gravity

Daily thereafter 1:

  • All above parameters
  • Complete blood count
  • LDH, albumin, serum osmolality
  • Blood gases and acid-base status
  • Electrocardiogram
  • Body weight

Renal Replacement Therapy

Consider dialysis for 1, 3:

  • Refractory hyperkalemia
  • Severe hyperphosphatemia
  • Volume overload unresponsive to diuretics
  • Symptomatic uremia
  • Acute kidney injury not responding to medical management

Critical Pitfalls to Avoid

  1. Never give allopurinol with rasburicase - causes xanthine accumulation 1

  2. Blood sample handling for uric acid - rasburicase degrades uric acid at room temperature; immediately place samples on ice and complete assay within 4 hours 2

  3. Don't alkalinize urine with rasburicase - increases calcium phosphate precipitation 1

  4. Screen for G6PD deficiency before rasburicase - can cause life-threatening hemolysis 2, 1

  5. Previous TLS history - these patients need nephrology consultation before restarting therapy and are candidates for prophylaxis with subsequent treatments 1

  6. Don't underestimate solid tumors - while rare, TLS can occur in solid malignancies with high tumor burden and chemosensitivity 4, 5

The evidence strongly supports rasburicase superiority over allopurinol in high-risk patients, with one retrospective analysis showing dialysis rates of 2.6% with urate oxidase versus 16% with allopurinol 1.

References

3
Research

Tumor lysis syndrome: A clinical review.

World journal of critical care medicine, 2015

5
Research

[Tumor lysis syndrome: risk factors and treatment].

Wiener klinische Wochenschrift, 2005

Related Questions

Is it possible to obtain a downloadable file containing information on tumor lysis syndrome?
Can tumor lysis syndrome be managed with observation alone in a patient with creatinine 3 mg/dL, uric acid 20 mg/dL, calcium 7.6 mg/dL, phosphorus 4.18 mg/dL, LDH 238 U/L, and normal potassium?
What aggressive prophylaxis should be initiated for a patient who has not yet received any therapy and is at risk for tumor lysis syndrome?
In a patient with non‑Hodgkin lymphoma undergoing chemotherapy who now has markedly elevated uric acid, phosphate, and potassium, what is the most likely cause of his acute renal failure—hyperuricemia‑induced nephropathy or tumor lysis syndrome?
What is tumor lysis syndrome?
For nasogastric tube placement, is gastrografin (diatrizoate meglumine and diatrizoate sodium) required to confirm placement?
What is the definition of chronic kidney disease (CKD)?
What is the difference between pneumonia and pneumonitis?
Can the Henoch‑Schönlein purpura (IgA vasculitis) alone account for the colitis observed on imaging despite the arterial‑venous duplex study findings?
Do clopidogrel and ticagrelor belong to the same chemical/drug family?
Is it possible to obtain a downloadable file containing information on tumor lysis syndrome?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.